AZN · CIK 0000901832
ASTRAZENECA PLC
Annual figures as reported, FY2014–FY2025. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Revenue
$58.7B
▲ +8.6% vs FY2024
Net income
$10.2B
▲ +45.3% vs FY2024
Free cash flow
$11.8B
▲ +18.4% vs FY2024
Diluted EPS
$6.54
▲ +45.3% vs FY2024
Revenue
Annual, as reported
Net income
Annual, as reported
Profitability & returns
quality of earningsMargins
Share of revenue kept at each line
Gross marginOperating marginNet margin
Returns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationFree cash flow
Operating cash flow less capital expenditure
Operating cash flow
Net cash from operations
Shareholder returns
capital allocationCapital returned
Cash paid out as dividends and share repurchases
Dividends paidBuybacks
Diluted shares outstanding
Falling count means buybacks outpace dilution
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Net debt
Long-term debt less cash — negative means net cash
Growth rates
compounding, annualizedRevenue CAGR
+9.8%
3y
+17.2%
5y
+9.0%
10y
Net income CAGR
+45.9%
3y
+26.6%
5y
+13.7%
10y
Diluted EPS CAGR
+45.8%
3y
+21.8%
5y
+11.4%
10y
Free cash flow CAGR
+10.5%
3y
+25.1%
5y
+19.4%
10y
Share count change (split-adjusted)
+19.0%
5y
+23.5%
10y
Key ratios
derived per fiscal year| Fiscal year | Gross margin | Op. margin | Net margin | FCF margin | ROE | ROA | Current ratio | Debt / equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | 81.9% | 23.4% | 17.4% | 20.0% | 21.0% | 9.0% | 0.94× | 0.61× |
| FY2024 | 81.1% | 18.5% | 13.0% | 18.4% | 17.2% | 6.8% | 0.93× | 0.74× |
| FY2023 | 82.0% | 17.9% | 13.0% | 19.6% | 15.2% | 5.9% | 0.82× | 0.73× |
| FY2022 | 72.1% | 8.5% | 7.4% | 19.7% | 8.9% | 3.4% | 0.86× | 0.79× |
| FY2021 | 66.8% | 2.8% | 0.3% | 13.0% | 0.3% | 0.1% | 1.16× | 0.78× |
| FY2020 | 80.1% | 19.4% | 11.8% | 14.4% | 20.1% | 4.7% | 0.96× | 1.30× |
| FY2019 | 79.8% | 12.0% | 5.0% | 8.2% | 8.4% | 2.0% | 0.86× | 1.25× |
| FY2018 | 77.7% | 15.3% | 9.3% | 7.1% | 14.6% | 3.4% | 0.96× | 1.36× |
| FY2017 | 80.8% | 16.4% | 12.8% | 10.0% | 17.2% | 4.5% | 0.80× | 1.07× |
| FY2016 | 82.1% | 21.3% | 14.8% | 11.7% | 20.4% | 5.4% | 0.87× | — |
| FY2015 | 81.2% | 16.7% | 11.4% | 8.1% | 15.3% | 4.7% | 1.08× | — |
| FY2014 | — | — | — | — | — | — | — | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | $58.7B | $48.1B | $13.7B | $10.2B | $6.54 | $14.6B | $2.8B | $114.1B | $65.4B | $48.7B | $5.7B | $29.6B |
| FY2024 | $54.1B | $43.9B | $10.0B | $7.0B | $4.50 | $11.9B | $1.9B | $104.0B | $63.2B | $40.9B | $5.5B | $30.3B |
| FY2023 | $45.8B | $37.5B | $8.2B | $6.0B | $3.81 | $10.3B | $1.4B | $101.1B | $62.0B | $39.2B | $5.8B | $28.6B |
| FY2022 | $44.4B | $32.0B | $3.8B | $3.3B | $2.11 | $9.8B | $1.1B | $96.5B | $59.4B | $37.1B | $6.2B | $29.2B |
| FY2021 | $37.4B | $25.0B | $1.1B | $115.0M | $0.08 | $6.0B | $1.1B | $105.4B | $66.1B | $39.3B | $6.3B | $30.8B |
| FY2020 | $26.6B | $21.3B | $5.2B | $3.1B | $2.44 | $4.8B | $961.0M | $66.7B | $51.1B | $15.6B | $7.8B | $20.4B |
| FY2019 | $24.4B | $19.5B | $2.9B | $1.2B | $1.03 | $3.0B | $979.0M | $61.4B | $46.8B | $14.6B | $5.4B | $18.2B |
| FY2018 | $22.1B | $17.2B | $3.4B | $2.0B | $1.70 | $2.6B | $1.0B | $60.7B | $46.6B | $14.0B | $4.8B | $19.1B |
| FY2017 | $22.5B | $18.1B | $3.7B | $2.9B | $2.37 | $3.6B | $1.3B | $63.4B | $46.7B | $16.6B | $3.3B | $17.8B |
| FY2016 | $23.0B | $18.9B | $4.9B | $3.4B | $2.76 | $4.1B | $1.4B | $62.5B | $45.9B | $16.7B | $5.0B | — |
| FY2015 | $24.7B | $20.1B | $4.1B | $2.8B | $2.23 | $3.3B | $1.3B | $60.1B | $41.5B | $18.5B | $6.2B | — |
| FY2014 | — | — | — | — | — | — | — | — | — | $19.6B | — | — |
Latest filings
the most recent regulatory filings6-KADMISSION OF FURTHER SECURITIES TO TRADING2026-07-01 ↗6-KTOTAL VOTING RIGHTS2026-07-01 ↗11-KEmployee stock plan report2026-06-29 ↗6-KENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS2026-06-29 ↗6-KDATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC2026-06-29 ↗4OWNERSHIP DOCUMENT2026-06-16 ↗6-KTRUQAP APPROVED IN US FOR PROSTATE CANCER2026-06-15 ↗6-KADMISSION OF FURTHER SECURITIES TO TRADING2026-06-01 ↗6-KTOTAL VOTING RIGHTS2026-06-01 ↗6-KIMFINZI APPROVED IN US FOR EARLY BLADDER CANCER2026-05-29 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.